European Pharmaceutical Contractor (EPC) is designed to fill a unique position in pharmaceutical publishing. Providing a dedicated platform of communication and information for the international pharmaceutical contract market, it consists of a series of articles and case studies written by eminent figures in contractor groups and traditional multinational pharmaceutical companies.
Each quarterly edition examines areas of importance – both economic and technical – to contract research organisations, contract manufacturers, regulatory controllers, consultants and analysts. This enables regulatory bodies to link directly with policy-makers both in major contractor groups and pharmaceutical companies, and thereby convey regulatory information directly from the governing bodies, but also ensure debate between the policy-makers and consultancy groups.
Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.
Edited by
Dr Graham Hughes,
Consultant in
Pharmaceutical
Development
Published quarterly in
March, June,
September and December
Industry Events
Post Market Surveillance and Vigilance
25-26 February 2015, Movenpick Hotel Amsterdam City Centre, Amsterdam, The Netherlands
With more international markets moving towards
electronic submissions as well as the specific requirements from EU agencies,
it is essential that you are up to speed with latest requirements and
expectations. More info >>
PenThu® officially registered and available in the market
Gent, Belgium – January 14th, 2015 - Europital announces the
official launching and certification attainment of its latest product.
From January 2015 “Penthu®: The Future of Medical Management in Clinical
Trials” will be available in the market. More info >>
Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
More info >>
